Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 3/20 | 0.41 |
| ▸ | ESRRB | O95718 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297214 | 1.00 | KDM4E (0.42) | KDM4EF13A1BLMESRRGESRRB | |
| SCHEMBL567236 | 0.87 | NPC1 (0.47) | ALDH1A1CYP3A4MEN1KMT2ANPC1 | |
| SCHEMBL12721376 | 0.84 | CTSS (0.43) | KDM4EF13A1ESRRGESRRBCA2 | |
| SCHEMBL1625903 | 0.84 | CTSS (0.43) | KDM4EF13A1ESRRGESRRBCA2 | |
| SCHEMBL28014304 | 0.82 | SSTR4 (0.47) | KDM4EF13A1BLMESRRGESRRB | |
| SCHEMBL687546 | 0.77 | PPARA (0.48) | ALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL687545 | 0.77 | PPARA (0.48) | ALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL4343633 | 0.76 | S1PR1 (0.48) | — | |
| SCHEMBL4343640 | 0.76 | S1PR1 (0.48) | — | |
| SCHEMBL12721396 | 0.75 | NPC1 (0.44) | CA2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625950-B2 | Mono phosphoric acid mono-{2-amino-2-hydroxymethyl-4-[4-(3-phenoxy-propoxy)-phenyl]-butyl} ester; treatment, prevention of diseases or disorders mediated by lymphocytes interactions in transplantation; anticarcinogenic agent, antiinflammatory agent, antiproliferative agent, antidiabetic agent | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-7612238-B2 | Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20060211658-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| US-20060166940-A1 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1622860-A1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1539674-A1 | AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004096752-A1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004024673-A1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166940-A1 | Amino-propanol derivatives | ADRB1, ADRB3, ADRA1D | KDM4E 1747/4885F13A1 1072/4885BLM 4587/4885 |
| US-20060211658-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | S1PR1, S1PR3, S1PR2 | KDM4E 2384/4885F13A1 1365/4885BLM 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.